Here’s What the Street Thinks About Elanco Animal Health Incorporated (ELAN)

Core Insights - Elanco Animal Health Incorporated (NYSE:ELAN) is recognized as a promising healthcare stock priced under $50, with recent positive adjustments in its stock ratings and price targets from multiple financial institutions [1][2]. Group 1: Rating Updates - BofA raised its price target for Elanco to $28 from $25 on January 30, maintaining a Buy rating, citing stronger operational results [1]. - UBS increased its price target to $30 from $27 on January 29, also reaffirming a Buy rating [1]. - Piper Sandler upgraded Elanco to Overweight from Neutral on January 22, raising the price target to $30 from $24, indicating positive developments observed at the VMX conference [2]. Group 2: Business Overview - Elanco Animal Health is engaged in providing services and products aimed at preventing and treating diseases in both pets and farm animals, with a diverse portfolio that includes species such as cats, dogs, cattle, swine, poultry, and sheep [3].